 |
Vol.60 No.5 contents | Japanese/English |
 | Full Text of PDF (521K) Article in Japanese |
- Review Article -
New Strategies in the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Satoshi Watanabe11Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Japan
Platinum-doublet chemotherapy has shown an overall survival benefit for patients with advanced non-small cell lung cancer (NSCLC) and has been the standard of care for the first-line treatment of these patients. Recent evidence has demonstrated promising data concerning immune-checkpoint inhibitors (ICIs) and necitumumab, a humanized anti-EGFR monoclonal antibody, for the treatment of patients with advanced squamous NSCLC. We herein review the results of pivotal studies investigating ICIs and necitumumab and discuss new treatment strategies in the first-line treatment of advanced squamous NSCLC.
key words: Squamous non-small cell lung cancer, Necitumumab, Immune-checkpoint inhibitor
Received: June 10, 2020
Accepted: July 25, 2020
JJLC 60 (5): 379-384, 2020
